Imiquimod is a unique topical therapeutic agent useful in the treatment of external genital
and perianal warts (condyloma acuminata) in adults. The authors report a case of a 21-year …

Imiquimod, an imidazoquinoline amine, is approved for the topical treatment of external
anogenital warts induced by human papilloma virus. Several clinical trials have shown …

Applied topically, imiquimod induces the production of interferon-α plus other cytokines.
Because intralesional interferon is effective in the treatment of condylomata acuminata …

The efficacy of imiquimod in the treatment of genital warts is encouraging. 7 In a
randomized, double-blind, placebo-controlled study, eradication of all treated baseline warts …

Skip the header click to show the menu Menu Cart Login Login/Register Institutional Access
Access Options Enter words / phrases / DOI / ISBN / keywords / authors / etc Search Advanced …

Treatment of anogenital warts in children is difficult. Commonly used therapeutic regimes
can be painful, variably effective and recurrence rates are high. Imiquimod is a recently …

Long‐lasting cutaneous warts are a therapeutic challenge, especially widespread or
symptomatic recalcitrant warts in children. It can be speculated that natural immunity to these …

Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …

Cytodestructive or surgical therapy for patients with anogenital warts is frequently associated
with recurrence. In February 1997, the US Food and Drug Administration approved …

Background: Long-lasting cutaneous warts may represent an unbearable stigma to patients
and therefore pose a singular challenge for the physician. Generally, these warts are …